
MIG Capital
Description
MIG Capital, headquartered in Munich, Germany, stands as a leading European venture capital firm with a strong focus on early to mid-stage Deep Tech and Life Science companies. Established with a mission to back groundbreaking innovations, MIG Capital has built a reputation for identifying and nurturing disruptive technologies across various sectors, including biotechnology, medical technology, advanced materials, and cutting-edge software solutions. Their strategic approach emphasizes long-term partnerships with visionary founders, providing not just capital but also extensive operational support and access to a vast network of industry experts.
The firm's investment strategy is characterized by its capacity to deploy significant capital across a company's lifecycle. For initial investments, MIG Capital typically provides first cheques ranging from approximately $1.08 million (€1 million) to $5.4 million (€5 million). This initial commitment is often followed by substantial additional funding rounds, with total investments in a single portfolio company potentially reaching up to $16.2 million (€15 million) or more, demonstrating their commitment to scaling successful ventures. MIG Capital manages a substantial pool of capital, with assets under management exceeding $1.08 billion (€1 billion) across multiple funds, enabling them to support a diverse portfolio of high-potential startups.
MIG Capital boasts an impressive track record of success, having invested in over 40 companies since its inception. Their portfolio includes several notable success stories and exits that underscore their ability to pick winners. A prime example is the acquisition of Ganymed Pharmaceuticals by Astellas Pharma for a remarkable €422 million, highlighting MIG Capital's proficiency in identifying and scaling innovative biotech firms to significant exits. The firm is known for its hands-on involvement, offering strategic guidance, recruitment support, and market access to help their portfolio companies navigate complex growth phases and achieve their full potential.
This comprehensive support system, combined with their deep industry expertise and robust financial backing, positions MIG Capital as a preferred partner for ambitious deep tech and life science startups in Europe. Their commitment to fostering innovation and driving technological advancements continues to solidify their standing as a pivotal player in the European venture capital landscape.
Investor Profile
MIG Capital has backed more than 90 startups, with 4 new investments in the last 12 months alone. The firm has led 41 rounds, about 46% of its total and boasts 12 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series Unknown, Series A, Series B rounds (top funding stages).
- Majority of deals are located in Germany, Austria, France.
- Strong thematic focus on Biotechnology, Health Care, Manufacturing.
- Led 1 rounds in the past year.
- Typical check size: $1.1M – $5.4M.
Stage Focus
- Series Unknown (33%)
- Series A (27%)
- Series B (18%)
- Seed (9%)
- Series C (7%)
- Series D (4%)
- Private Equity (1%)
- Series E (1%)
Country Focus
- Germany (78%)
- Austria (8%)
- France (6%)
- Denmark (3%)
- Canada (2%)
- The Netherlands (2%)
- Finland (1%)
Industry Focus
- Biotechnology
- Health Care
- Manufacturing
- Software
- Medical
- Medical Device
- Health Diagnostics
- Information Technology
- Semiconductor
- Cleantech
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.